Patients with EGFR mutations have lower tumor mutation burden (TMB) levels and reduced tumor-infiltrating lymphocytes compared with other patients; they thus have lower immunogenicity and antitumor immunity22,23. This evidence concerns the gene EGFR and neoplasm.